TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03502031
Drug: Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 24 months.
Study: NCT03093103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
Study: NCT02533700
Drug: CEOP/IVE/GDP chemotherapy regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4
Study: NCT02533700
Drug: CEOP chemotherapy regimen for 6 cycles
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
Study: NCT05954052
Drug: Glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giving supplement orally
Study: NCT02293941
Drug: JKB-122 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomized to receive JKB-122 5mg for 12 weeks
Study: NCT00918749
Drug: 100 mg
Normalized name: urea 100 MG
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
Study: NCT05110170
Drug: LY01005
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY01005 was administered as 3 intramuscular (IM) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
Study: NCT05110170
Drug: ZOLADEX® 3.6 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOLADEX® was administered as 3 Subcutaneous (SC) injections, 28 days apart. As concomitant medications, tamoxifen (10 mg/tablet, 1 tablet/time) was orally administered twice per day during the whole study period.
Study: NCT00830089
Drug: Levobupivicaine 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
Study: NCT03130881
Drug: PLB1003
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1003 is a capsule and is administered orally.
Study: NCT01073787
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg of normal saline will be administered over 30 minutes
Study: NCT00712140
Drug: parenteral chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: per the local institutional protocols either concurrently with or sequentially to trastuzumab
Study: NCT00939822
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg Simvastatin/day
Study: NCT00939822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00085787
Drug: ARRY-142886, MEK inhibitor; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Study: NCT01903824
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos formulated to match each active drug
Study: NCT01978327
Drug: GSK2647544
Approvals — FDA: no, EMA: no, PMDA: no
Description: repeat dose
Study: NCT01145209
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01035645
Drug: GSK1070806
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation.
Study: NCT00652327
Drug: Double Statin (simvastatin, atorvastatin, or pravastatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
Study: NCT04767243
Drug: open flap debridement and filled Bioactive glass (Perioglas®) and A-PRF
Approvals — FDA: no, EMA: no, PMDA: no
Description: After phase 1 therapy, surgical procedure would be carried out in the selected patients under aseptic conditions. Full thickness mucoperiosteal Kirkland flap would be raised on both buccal and lingual sides using periosteal elevator. Pocket lining epithelium would be removed and a thorough debridement and root planing would be done in the intrabony defect by using Gracey curettes and universal curettes. After placement of perioglas with A-PRF in bony defect site the mucoperiosteal flaps would be sutured for complete soft tissue closure.
Study: NCT03943472
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2/d
Study: NCT03692429
Drug: CYAD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
Study: NCT03692429
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU, leucovorin and oxaliplatin
Study: NCT03692429
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU, leucovorin and irinotecan
Study: NCT03943472
Drug: Immune inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune inhibitors
Study: NCT00004426
Drug: gonadotropin releasing hormone
Normalized name: Gonadotropin releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04155047
Drug: Placebo administered by Magnair
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhalation Solution
Study: NCT01599494
Drug: MK-8962
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962.
Study: NCT01599494
Drug: recFSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
Study: NCT04817332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT01635829
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
Study: NCT02293941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomized to receive comparable placebo for 12 weeks
Study: NCT04514510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicified microcrystalline cellulose NF, Ascorbic acid, Nicotinic acid, Mg stearate, Silica and Colloidal Anhydrous Ph. Eur./Colloidal Silicon dioxide USP/NF.~Placebo give at 1000 mg, once daily by mouth for 28 days.
Study: NCT03509922
Drug: Anplag Tab. 100mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarpogrelate hydrochloride 100mg bid for 24 weeks
Study: NCT01368263
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy
Study: NCT03509922
Drug: Anplag Tab. 100mg tid
Approvals — FDA: no, EMA: no, PMDA: no
Description: sarpogrelate hydrochloride 100mg tid for 24 weeks
Study: NCT00507936
Drug: ABT-894
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-894 1 mg capsule BID throughout treatment period
Study: NCT00507936
Drug: ABT-894
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-894 2 mg capsule BID throughout treatment period
Study: NCT00507936
Drug: ABT-894
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-894 4 mg capsule BID throughout treatment period
Study: NCT00507936
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule BID throughout the treatment period
Study: NCT00972179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous or intravenous injection.
Study: NCT01994720
Drug: Acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
Study: NCT00110877
Drug: LPV/rtv
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 400mg LPV tablet twice daily with 100mg RTV
Study: NCT01152554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral, twice daily for 52 weeks
Study: NCT00110877
Drug: TMC114/rtv
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 300mg TMC114 tablets twice daily with 100mg RTV
Study: NCT04078711
Drug: Qianyangyuyin 20g Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20g, Granule, bid, po, 6 months
Study: NCT04078711
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
Study: NCT00190788
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02053493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo
Study: NCT04086810
Drug: DCCR
Normalized name: Diazoxide Choline Controlled-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration
Study: NCT00847197
Drug: MK1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
Study: NCT02216383
Drug: Syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
Study: NCT01534273
Drug: LY2886721
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01534273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01493245
Drug: JNS020QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
Study: NCT00847197
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
Study: NCT00627055
Drug: LPV/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
Study: NCT00285025
Drug: SR57667B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03950843
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of CKD-825~* Dosage Form: capsule~* Dosage: NA~* Frequency: QD administration
Study: NCT04563208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered on Days 1-5
Study: NCT04563208
Drug: DuACT
Normalized name: Sus scrofa bile duct preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day1: RBV 600 mg BID and NTZ 500 mg BID Days 2-5: RBV 400 mg BID and NTZ 500 mg BID
Study: NCT02854787
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolus of 0,2 mcg/kg
Study: NCT01555476
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
Study: NCT01555476
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
Study: NCT00627055
Drug: LPV/r + TDF/FTC or TDF/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
Study: NCT02064348
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for s.c. injection or tablets for oral administration
Study: NCT03949751
Drug: Acne Crème Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
Study: NCT03343327
Drug: Chronocort®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20mg Chronocort® administered in one treatment period
Study: NCT03343327
Drug: Cortef®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 20mg Cortef® administered in one treatment period
Study: NCT02938741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-ATG 2.5MG/KG\*4days were not used in the conditioning
Study: NCT00738894
Drug: Antiplatelet Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of one of three regimen options specified in protocol
Study: NCT03806101
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single 10 mg dose of rosuvastatin
Study: NCT04064073
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, once daily single dose
Study: NCT00620165
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
Study: NCT00633880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study: NCT02104297
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil infused during operation 0.2 mcg/kg/min
Study: NCT02559895
Drug: ALD403
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02559895
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712905
Drug: INCB059872
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth.
Study: NCT04870229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04751175
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01540864
Drug: HPP404
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily for 26 weeks
Study: NCT01540864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily for 26 weeks
Study: NCT02217501
Drug: Acetylsalicylic acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
Study: NCT02111317
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03504618
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day
Study: NCT01170325
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00768690
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
Study: NCT00768690
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
Study: NCT04675242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of NCX 4251 Ophthalmic Suspension dosed once daily
Study: NCT00931632
Drug: Inhaled Nitric Oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
Study: NCT00931632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen gas will be administered in the same manner as the experimental drug.
Study: NCT00263198
Drug: PTK787/ZK222584
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03050827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active placebo for 3% oxybutynin
Study: NCT03110133
Drug: Full Spectrum Microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered donor derived microbiota
Study: NCT03110133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for CP101
Study: NCT03890458
Drug: DEVIT-3
Normalized name: DEVILS CLAW
Approvals — FDA: no, EMA: no, PMDA: no
Description: The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
Study: NCT03995888
Drug: rhPSMA-7.3 (18F) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand for PET CT scanning
Study: NCT01153256
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
Study: NCT01153256
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
Study: NCT01160991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are given at 8:00 a.m.
Study: NCT00329147
Drug: desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00245921
Drug: Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00543712
Drug: PRO95780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT01077427
Drug: Gemcitabine + Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles
Study: NCT00770029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Study: NCT02509351
Drug: placeboo
Approvals — FDA: no, EMA: no, PMDA: no
Description: women will recive 2 identical tablets as placeboo